- Home
- IPHA vs CRBP Comparison
IPHA vs CRBP Comparison
Compare IPHA & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | CRBP |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | France | United States |
| Employees | 174 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 134.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | IPHA | CRBP |
|---|---|---|
| Price | $1.22 | $8.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.75 | ★ $45.60 |
| AVG Volume (30 Days) | 11.9K | ★ 191.8K |
| Earning Date | 03-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $28.31 | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.31 | $4.64 |
| 52 Week High | $2.63 | $20.56 |
Technical Indicators
Market Signals| Indicator | IPHA | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 21.88 | 48.37 |
| Support Level | N/A | $7.45 |
| Resistance Level | $1.88 | $9.69 |
| Average True Range (ATR) | 0.08 | 0.65 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 2.79 | 34.04 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.